This Q sales numbers not a surprise. Zero insider buying in last Q and zero institutional buying (institutional ownership still at 13%). The truth be told Probuphine is a flop and mostly so because of the incompetence at Titan and Braeburn. The only future is to sell off Titan for it's IP and proneura's future other drug applications as Sunil and Co. will just run the company further into the ground.
Market Makers suckered a whole new round of bagholders in the $2 range this last run up to mid $2 range.
all is not assured for the injectables ..not for Braeburn or INVVY... at some point Apple Tree may pull the plug on Braeburn rather than pour another nickel into mounting losses (could be happening right now) .. remember from S1, that was one of the concerns of auditors?... no one's buying Braeburn's song.. so someone may step up & swoop the whole caboodle at a discount .. TTNP & probuphine from Apple Tree..we'll see
News 
Market Data 
Discover 
AI
